{"anticipatedPostingDate":"2027-12","denomUnitsSelected":"Participants","description":"ORR: % of participants with best overall response of confirmed stringent complete response (sCR), CR, very good partial response (VGPR) or PR per IMWG criteria. sCR: CR \\& normal serum free light chain (sFLC) ratio \\& absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum \\& urine, disappearance of any soft tissue plasmacytoma \\& \\<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum \\& urine M-protein detectable by immunofixation but not on electrophoresis; or \\>=90% reduction in serum M-protein \\& urine M-protein level \\<100mg/24h. PR: \\>=50% reduction in serum M-protein \\& reduction in 24h urinary M-protein by \\>=90% or \\<200 mg/24h. If serum \\& urine M-protein were unmeasurable, VGPR \\& PR: \\>=90% \\& \\>=50% decrease in difference respectively between involved \\& uninvolved sFLC levels \\& if present at baseline, \\>=90% \\& \\>=50% reduction in soft tissue plasmacytomas' size.","reportingStatus":"NOT_POSTED","timeFrame":"From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 20.14 months)","title":"Objective Response Rate as Per IMWG Criteria by Investigator Assessment","type":"SECONDARY"}